IQ-AI subsidiary Imaging Biometrics achieves significant milestone in development of zero percent Ga

0 31

IQ-AI Limited (LON:IQAI) said its subsidiary Imaging Biometrics (IB) has achieved a “significant milestone” in the development of a zero percent Gadolinium-based contrast agents (GBCA) approach.

Gadolinium is a chemical element that is sometimes used in medical scans such as magnetic resonance imaging (MRI) to improve the clarity of images of the body’s internal structures. However, IQ-AI highlighted “longstanding toxicity concerns” regarding the use of the element in the body.

READ: IQ-AI entering an exciting phase in its development

The company said IB’s initial goal is focused on the generation of a brain image equivalent to a post-contrast image using information provided from anatomical and functional images acquired without any administration of exogenous contrast material such as Gadolinium.

IB has developed a deep learning (DL) algorithm using T1-weighted, T2, and fluid attenuation inverse recovery (FLAIR) as inputs. These inputs are common MR sequences collected as part of routine brain scans. The DL model then extracts feature-derived information to create images analogous to post-contrast images.

IQ-AI said the model is now ready to begin the next phase of development, which includes comparing the algorithm’s output to “ground truth”, images acquired with GBCA, on a much larger dataset from multiple scanner vendors and field strengths.

The company added that translating the DL technology to routine clinical use will represent a “significant disruption to current practice”, with GBCAs having been used in medical imaging since 1988, although it said its pipeline for distributing a validated solution is “already well established”.

IQ-AI is also awaiting approval for a patent from the US Patent and Trademark Office which was filed in October last year.

Shares in IQ-AI added 9.8% to 5.6p in early deals on Friday.

Leave A Reply

Your email address will not be published.